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Abstract: Although CD44 was overexpressed and considered as a useful prognostic marker in renal cell carcinoma, 
the prognostic role of CD44s in clear cell renal cell carcinoma (ccRCC) remains controversial. Moreover, the correla-
tion and prognostic significance of CD44s and its downstream signaling target pSTAT3 are unclear in ccRCC. In this 
study, 75 pairs of carcinoma and paired adjacent non-tumor renal tissue samples were collected from patients with 
localized ccRCC who underwent a nephrectomy. The expression levels of CD44s and pSTAT3 were analyzed using 
immunohistochemistry. Correlations between CD44s/pSTAT3 expression and clinical and pathological character-
istics were determined using x2 test, Kaplan-Meier analysis and Cox’s proportional hazards model. We found that 
CD44s is highly expressed in 46.67% of tumor tissues, and its high expression was significantly associated with 
high tumor grade (P < 0.001), large tumor size (P = 0.009) and advanced T stage (P = 0.004). A strong correlation 
exists between high expression of CD44s and pSTAT3 (r = 0.4013, P = 0.0004). The joint over expression of CD44s 
and pSTAT3 was present in 42.66% of tumor specimens and had an additive negative impact on overall survival. 
Patients with CD44shighpSTAT3high expression had significantly poor survival as compared to patients with CD44slow-
pSTAT3low tumor expression (P = 0.024), though the concurrent overexpression of CD44s and pSTAT3 was not an 
independent prognostic factor for overall survival. Our data indicate that expression of both CD44s and pSTAT3 in 
ccRCC is associated with advanced tumor stage and patient survival. The conclusions from this study may improve 
the prediction of ccRCC prognosis information when CD44s and pSTAT3 expression are evaluated together with 
classical clinicopathological parameters.
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Introduction 
Renal cell carcinoma (RCC) is the most lethal 
urologic cancers, with more than 200,000 new 
cases diagnosed worldwide annually [1]. The 
most common form of kidney cancer is RCC of 
which 70-80% of cases are defined as clear cell 
renal cell carcinoma (ccRCC) [2]. Currently, the 
only potential curative treatment is surgery. 
However, 20-30% of patients with RCC experi-
ence local or distant recurrence within 5 years 
after an initial nephrectomy [3]. Therefore, the 
recurrence of RCC after surgery is a major fac-
tor limiting patient survival. Identification of 
new biomarkers to predict tumor relapse and 
patient survival remains a subject of funda-
mental importance. 
To date, the traditional assessment of progno-
sis for RCC patients relies mainly on tumor 
stage, nuclear grade, and histological features 
[4]. However, these parameters are neither reli-
able nor accurate for predicting the therapeutic 
response [5, 6], and studies to discover addi-
tional prognostic markers is greatly needed. 
More importantly, the ability to predict which 
patients will develop recurrence after surgery is 
valuable, allowing physicians to make more 
informed decisions on the follow-up schedule 
and additional treatment. 
CD44, a ubiquitous multifunctional cell surface 
adhesion molecule, has been implicated in 
tumorigenesis, progression and tumor recur-
rence. Additionally, CD44 is recognized as a 
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potential biomarker in a variety of human can-
cers [7]. Several isoforms of CD44 have been 
identified as the result of alternative post-tran-
scriptional splicing. The standard form, CD44s, 
is the main receptor for hyaluronate acid (HA) 
and has been implicated in lymphocyte hom-
ing, tissue regeneration, and tumor cell dissem-
ination [7]. Moreover, CD44s has been identi-
fied as a marker of tumor initiating cells (TICs) 
[7], and plays an essential role in cells undergo-
ing epithelial-mesenchymal transition (EMT) 
[8]. We recently identified CD44+ subpopulation 
(CD133+/CD44+) as the putative pancreatic 
TICs; and found that CD44s plays an important 
role in TICs maintenance, radiation resistance 
and tumor recurrence [9, 10]. Although CD44s 
acts as a potential prognostic factor, contradic-
tory results have been reported concerning 
CD44s overexpression in relation to tumor 
development and progression in different 
tumors types. Patients with CD44s overexpres-
sion were reported to have better survival in 
bladder cancer, myxofibrosarcoma and gastro-
intestinal cancer [11, 12], while CD44s overex-
pression was associated with poor survival in 
pharyngeal and laryngeal cancer patients [13]. 
In oral cancer, prostate cancer and ovarian car-
cinoma, no clear association was revealed 
between CD44s expression and prognosis [13-
15]. In RCC, elevated CD44 expression was 
reported, but its prognostic role in RCC remains 
controversial; some studies support the role of 
CD44 as a prognostic marker [1, 4, 16] while 
other studies were unable to confirm the impor-
tance of CD44 including CD44s as a predictor 
of survival [17, 18]. Thus, the role of CD44s as 
a biomarker for ccRCC warrants further investi-
gation to confirm its utility in patients with 
ccRCC, which stimulated our current study.
CD44 can activate a number of signaling mole-
cules, including signal transducer and activator 
of transcription 3 (STAT3). STAT3 is structurally 
and functionally coupled in the HA/CD44 sig-
naling pathway and known as a proximal medi-
ator of CD44-dependent chemo-resistance in 
stem cell like cells [19, 20]. As a oncogenic 
transcription factor, STAT3 modulates the tran-
scription of responsive genes involved in cell 
differentiation, proliferation, apoptosis, angio-
genesis, metastasis, immune responses, or- 
chestrating tumor-associated inflammation 
[21] and maintaining self-renewal of CD44+C- 
D24- stem cell like cells [22]. Tumor cell lines 
bearing constitutively activated STAT3 require 
continued STAT3 activation, a phenotype that 
has been termed “oncogene addiction” [23]. 
The majority of human malignancies demon-
strate elevated levels of constitutively activat-
ed STAT3 and the elevated levels of activated 
STAT3 have been associated with poor progno-
sis including in RCC patients [23, 24]. We 
recently showed that pSTAT3 acts downstream 
of CD44s activation, and that CD44s and 
pSTAT3 were co-overexpressed in pancreatic 
cancer, suggesting their potential connection in 
tumor development and progression [10, 25]. 
However, the correlation of CD44s co-overex-
pression with pSTAT3 and their clinical rele-
vance in ccRCC is currently unknown. 
In this paper, we examined CD44s and pSTAT3 
co-overexpression in carcinoma and paired 
Table 1. Patient’s characteristics
Features No. patients (%)
Age, year
    Mean, Median (range) 58.7, 57 (29~82)
Gender
    Male 50 (66.7%)
    Female 25 (33.3%)
Tumor size, cm
    Mean, Median (range) 6.7, 6 (2.3~15)
Tumor grade
    I 4 (5.3%)
    II 45 (60%)
    III 21 (28%)
    IV 5 (6.7%)
T stage
    T1 37 (49.3%)
    T2 25 (33.3%)
    T3 13 (17.3%)
N stage
    N0 69 (93.2%)
    N1+N2 5 (6.8%)
AJCC clinical stage
    1 33 (44%)
    2 24 (32%)
    3 17 (22.7%)
    4 1 (1.3%)
Overall Survivala, month
    Mean, Median (range) 52.6, 63 (2~74)
    live 29 (67.4%)
    dead 14 (32.6%)
aOnly 43 cases have available survival data.
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adjacent non-tumor renal tissue from 75 pa- 
tients with ccRCC, and determined the correla-
tion between their individual expression and 
co-expression with various clinicopathological 
features, and analyzed their prognostic value 
for survival of patients with ccRCC. 
Materials and methods
Patient samples 
Tissue samples were collected from 75 patients 
with ccRCC who underwent a radical or partial 
nephrectomy between 2006 and 2012. The 
clinical, pathological, and treatment informa-
tion, together with follow-ups were obtained 
through medical record review. The following 
histopathological factors were evaluated: 
tumor histologic subtype, grade, tumor size, 
location, TNM stage, and pathological stage 
according to the 2009 American Joint Co- 
mmittee on Cancer (AJCC) TNM staging system 
(7th edition). Follow-up data was included: date 
of nephrectomy, survival status, date of death, 
and/or date of last follow-up. This study was 
reviewed and approved by the Institutional 
Review Board of the Fourth Military Medical 
University.
Tissue microarray
A tissue microarray (TMA) constructed from 
formalin-fixed, paraffin-embedded tissue blo- 
cks from 75 patients with ccRCC was pur-
chased from the National Engineering Center 
for Biochip (Shanghai, China). First, representa-
tive tumor areas and paired adjacent non-neo-
plastic tissues were carefully selected by a 
trained pathologist from a hematoxylin and 
eosin-stained section of each donor block. 
Each tissue sample was represented by three 
cylindrical core tissue biopsies (diameter 0.6 
mm) collected using a manual tissue arrayer 
(MTA1 Tissue Arrayer SY010103, Beecher 
instruments Inc, Sun Prairie, Wisconsin, USA). 
After tissue cores were extracted from tissue 
blocks, 4-μm thick sections were cut and trans-
ferred to an adhesive-coated slide. The pres-
ence of tumor tissue on the arrayed samples 
was verified on a hematoxylin-eosin-stained 
section.
Immunohistochemistry
TMA slides were dried at 63°C for one hour 
before staining. All procedures were performed 
at room temperature as previously described 
[26]. Briefly, sections were dewaxed in xylene 
and rehydrated in a graded alcohol series. 
Sections were then washed in water before 
antigen retrieval using a Leica ST5010 Aut- 
ostainer (Leica Microsystems Inc., Buffalo 
Grove, IL, United States) with 10 mM sodium 
citrate buffer (pH 5.96) at 100°C in an auto-
clave for 5 minutes. The sections were then 
treated with 3% hydrogen peroxide for 15 min 
to block endogenous peroxidase. Primary anti-
body was prepared as: mouse CD44s monoclo-
nal antibody (Abnova, Taipei City, Taiwan) dilut-
ed at 1:200, and rabbit pSTAT3 monoclonal 
antibody (Epitomics, Inc., California, USA) dilut-
ed at 1:50 with background-reducing diluents 
Figure 1. Representative images of CD44s immunohistochemistry staining in clear cell renal cell carcinoma tissues. 
(A) Negative control, (B) non-neoplastic tissue, (C) no staining, (D) weak staining intensity, (E) intermediate staining 
intensity and (F) strong staining intensity. Bar, 101.3 µm. Magnification: 400X.
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(Dako, Carpinteria, CA, USA). After 30 minutes 
of incubation with primary antibody in a humid-
ity chamber, the slides were incubated for 30 
minutes with an EnVision™/HRP anti-rabbit or 
anti-mouse solution (Dako, Glostrup, Denmark). 
Reaction products were visualized with diami-
nobenzidine plus substrate-chromogen solu-
tion applied for 5 minutes. The slides were 
counterstained with Meyer’s hematoxylin and 
mounted. Careful rinses with several changes 
of phosphate-buffered saline (PBS) were per-
formed between each stage of the procedure. 
Negative controls were prepared by excluding 
the primary antibody.
TMA scoring
The immunohistochemical staining results 
were scored by two independent pathologists, 
who were unaware of clinicopathological details 
of the patients. Expression staining was scored 
based on the localization of CD44s on the sur-
face of cells and nuclear pSTAT3. The percent-
age of positive stained cells was scored as: 
group 0 had no positive stained cells; group 1, 
2, and 3 had 1-25%, 26-75% and > 75% posi-
tive stained cells. The intensity of positive 
stained cells was scored into four groups: group 
0 displayed no visible difference as compared 
to the negative control sample; the positive 
stained cells of group 1, 2 and 3 were light 
brown, mid-brown and dark brown, with the 
same intensity covering more than 75% of the 
staining area. For tissue sample with surface 
bound CD44s and phospho-STAT3-positive 
nuclei: the samples with no staining were 
defined as negative expression; the samples 
with 1+ staining ≤ 50% of cells or 2+ staining ≤ 
25% of cells were defined as weak expression; 
the samples with 1+ staining > 50% of cells or 
logical features as well as patient survival. The 
Kaplan-Meier method and the log-rank test 
were used to compare overall survival, defined 
as the time from surgery until death (living 
patients were censored at the time of their last 
follow-up). A Cox’s proportional hazards model 
was performed to analyze the correlation of 
CD44s/pSTAT3 expression on patient survival 
and determine the independent prognostic 
effects of these factors. A P-value of less than 
0.05 was considered statistically significant. All 
statistical analyses were conducted using 
SPSS statistical software (vers. 16.0; SPSS, 
Inc., Chicago, IL, USA).
Results
Patient characteristics
The patient characteristics are summarized in 
Table 1. The patients ranged from 29 to 82 
years of age (average 58.7 years), and 66.7% of 
the patients were male. Of the patients, 44, 32, 
22.7 and 1.3% were presented with AJCC clini-
cal stage 1-4 respectively; and 49.4, 33.3 and 
17.3% had pT1-pT3 primary tumors respectively 
with average tumor size of 6.7 cm (range, 2.3-
15 cm). Tumor grading demonstrated grade 1-4 
lesions in 5.3, 60, 28 and 6.7% of patients, 
respectively. Over 6 years, 14 (32.6%) patients 
died of the ccRCC.
CD44s expression and its correlation with 
clinicopathological features in ccRCC
In resected primary tumors from 75 patients 
with ccRCC, CD44s expression patterns were 
investigated by immunohistochemistry. As 
shown in Figure 1, CD44s was diversely stained 
in the membrane and cytoplasm of cells. In 
Table 2. CD44s expression in non-neoplastic tissue and ccRCC
CD44s expression levels† Non-neoplastic tissue (n = 75) ccRCC (n = 75)
Negative 68% (51/75) 18.67% (14/75)
Weak 22.67% (17/75) 34.66% (26/75)
Moderate 8% (6/75) 20% (15/75)
Strong 1.33% (1/75) 26.67% (20/75)*
†Expression levels of CD44s are scored as: the samples with no staining were defined 
as negative expression (Negative); the samples with 1+ staining ≤ 50% of cells or 2+ 
staining ≤ 25% of cells were defined as weak expression (Weak); the samples with 
1+ staining > 50% of cells or 2+ staining between  26-75% of cells or 3+ staining ≤ 
25% of cells were defined as moderate expression (Moderate); the samples with 2+ 
staining > 75% of cells or 3+ staining > 25% of cells were defined as strong expres-
sion (Strong). *Statistically significant (P < 0.05); Estimated by χ2 test as compared to 
non-neoplastic tissue.
2+ staining between 26- 
75% of cells or 3+ staining ≤ 
25% of cells were defined as 
moderate expression; the 
samples with 2+ staining > 
75% of cells or 3+ staining > 
25% of cells were defined as 
strong expression [25].
Statistical analysis
Pearson’s x2 test was used 
to assess the correlation 
between CD44s/pSTAT3 ex- 
pression and clinicopatho-
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non-neoplastic tissues, CD44s has negative to 
weak expression; while in ccRCC its expression 
is greatly enhanced. The percentage of strong 
CD44s expression was significantly higher in 
cancer as compared to that of paired non-neo-
plastic tissue (26.67% vs. 1.33%, P < 0.001, 
Table 2). For further analysis, we divided 
patients into CD44s low expression group (neg-
ative to weak expression) and CD44s high 
expression group (moderate to strong expres-
sion), with the ratio of CD44s high expression in 
ccRCC significantly greater than that of in non-
neoplastic tissue (46.67% vs. 9.33%, P < 
0.001).
We next investigated the correlation between 
CD44s expression and clinicopathological par- 
ameters. First, we examined the association of 
CD44s expression with survival time in avail-
able 43 ccRCC patients using Kaplan-Meier 
survival analysis. As shown in Figure 2A, 75% 
of patients with high CD44s expression sur-
vived on average 32 months as compared to 
longer than 61 months for patients with low 
expression of CD44s (P = 0.086) [hazard ratio 
(HR) = 2.673, 95% confidence interval (CI) = 
0.83 to 8.611, P = 0.099]. The 5-year survival 
rate for patients whose tumors expressed low 
and high levels of CD44s was of 85% and 
60.9%, respectively. No significant correlation 
exists in age, gender, N stage, AJCC clinical 
stage and patient survival (Table 3). However, 
high expression of CD44s was significantly cor-
related with high tumor grade (P < 0.001), large 
tumor size (P = 0.009) and advanced T stage (P 
= 0.004).
Correlation between concurrent CD44s/
pSTAT3 expression and clinicopathological 
features in ccRCC
We previously reported that CD44s promotes 
tumor-initiation and post-radiotherapy recur-
Figure 2. CD44s/pSTAT3 expression associated with patients’ overall survival. A: Kaplan-Meier analysis of over-
all survival in 43 patients comparing high and low CD44s expression groups. B: Kaplan-Meier analysis of overall 
survival in 43 patients comparing high and low pSTAT3 expression groups. C: Correlation analysis between CD44s 
and pSTAT3 expression in ccRCC patients. D: Kaplan-Meier analysis of overall survival for 43 patients based on 
CD44s and pSTAT3 expression. CD44shighpSTAT3high: patients with tumors overexpressing both proteins; CD44shigh 
or pSTAT3high: patients with tumors overexpressing only one of the two proteins; CD44slowpSTAT3low: patients with 
tumors low expressing both proteins.
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CD44highpSTAT3low 4% (3/75) 
CD44slowpSTAT3high 34.67% (26/75)
CD44shighpSTAT3high 42.66% (32/75)
Pearson r = 0.4013 (95% confidence interval: 0.1917-
0.5753), P = 0.0004.
rence through pSTAT3 signaling [10]. However, 
their relationship in ccRCC was unclear. Thus, 
we first studied the nuclear pSTAT3 expression 
in the same 75 pairs of ccRCC tissue samples 
in order to understand better the correlation 
between CD44s and pSTAT3 expression on 
patient outcome. Differently from CD44s, both 
tumor tissues and adjacent non-neoplastic tis-
2C). In 46 of 75 (61.33%) tumour specimens, 
concurrent CD44s and pSTAT3 expression was 
found, which includes concurrent high expres-
sion in 42.66% and concurrent low expression 
in 18.67% (Table 4). Taken together, neither 
CD44s nor pSTAT3 alone significantly affect 
patient survival and prognosis in patients with 
localized ccRCC although they are significantly 
correlated with a variety of clinicopathological para- 
meters.
As CD44s and pSTAT3 were highly correlated in 
ccRCC, we thus divided patients into three dis-
tinct subgroups, identified by the expression of 
CD44s and pSTAT3 antigens. As shown in 
Figure 2D, patients with tumors highly express-
ing both antigens experienced the poorest clini-
cal outcome. In this population of patients 
(CD44shigh/pSTAT3high), the average survival 
Table 3. Correlation between CD44s/pSTAT3 expression and clinico-
pathological features
Characteristics








(n = 58) P value
†
Age 0.716 0.975
    ≤ 60 25 21 10 36
    > 60 14 14 6 22
Gender 0.870 0.435
    Male 27 23 10 40
    Female 13 12 7 18
Tumor size 0.009 0.043
    ≤ 7 (cm) 30 16 14 32
    >7 (cm) 10 19 3 26
Tumor grade < 0.001 0.001
    I+II 34 15 17 32
    III+IV 6 20 0 26
T stage 0.004 0.002
    T1 26 11 14 23
    T2+T3 14 24 3 35
N stage 1 0.475
    N0 36 23 17 52
    N1+N2 3 2 0 5
AJCC clinical stage 0.386 0.021
    1+2 32 25 17 40
    3+4 8 10 0 18
pSTAT3 0.006 -
    Low 14 3 - -
    High 26 32 - -
*Low (negative to weak expression), High (moderate to strong expression). †Estimated 
by χ2 test.
sues have high level of pS- 
TAT3 expression in ccRCC 
due to the role of pSTAT3 as 
an inflammatory factor. The 
percentage of tumor tissue 
samples with high nuclear 
expression of pSTAT3 was 
76.33%, which was signifi-
cantly greater than that of 
CD44s (46.67%, P < 0.001). 
Similarly, high expression of 
nuclear pSTAT3 was signifi-
cantly associated with poor 
survival (P = 0.036), high 
tumor grade (P = 0.001), 
large tumor size (P = 0.043), 
advanced T stage (P = 
0.002) and AJCC stage (P = 
0.021) (Figure 2B, Table 3). 
However, univariate analy-
ses showed that pSTAT3 
was not a survival predictor 
for patients with localized 
ccRCC [hazard ratio (HR) = 
31.575, 95% confidence int- 
erval (CI) = 0.156 to 6383, 
P = 0.202].
Remarkably, high expressi- 
on of membrane bound 
CD44s was significantly as- 
sociated with high expres-
sion of nuclear pSTAT3 (P = 
0.006) with strong correla-
tion between them (r = 
0.4013, P = 0.0004, Figure 
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time for 75% of patients was 32 months; in con-
trast to an intermediate prognosis in 75% of 
patients highly expressing either CD44s or 
pSTAT3 with an average survival of 61 months. 
Finally, patients with low expression of both 
antigens in their tumors carried the best prog-
nosis. In our patient cohort, no death occurred 
in the 6 patients with low expression of CD44s/
pSTAT3 after monitoring over 6 years post oper-
ation. Statistically, patients with high expres-
sion of both antigens had a poor overall survival 
as compared to patients with low expression of 
both antigens (P = 0.024, log-rank test).
In regards to the pathological features of the 
tumor samples, there were significant differ-
ences in tumor grade (P < 0.001), tumor size (P 
= 0.006) and T stage (P = 0.001) among 
patients with high expression of both antigens, 
high expression of either CD44s or pSTAT3 and 
low expression of both antigens (Table 5). Using 
the univariate analyses method, we discovered 
that age (P = 0.028), tumor grade (P = 0.024) 
and CD44s/pSTAT3 co-expression (P = 0.028) 
were significant risk factors affecting the over-
type of kidney cancer and its molecular patho-
genesis is not completely understood [27]. 
Another reason is the relative homogeneous 
features within the population. 
In this study, we show that the overexpression 
of CD44s was significantly correlated with 
important clinical variables such as tumor 
grade, tumor size and T stage, but not with 
patient survival time, suggesting a limited prog-
nostic role of CD44s alone in patients with 
ccRCC. Additionally, our study revealed a 
significant correlation between the expression 
of CD44s and pSTAT3 in ccRCC. The co-expres-
sion of CD44shigh/pSTAT3high had an additive 
negative impact on patient survival, as com-
pared to patients with CD44slow/pSTAT3low 
expression in tumors.
Although it’s limited role in prognosis, CD44s 
could be a promising therapeutic target. In our 
study, we found a significant correlation be- 
tween high expression of CD44s and high 
tumor grade, reflecting a functional role for 
CD44s in maintaining a more embryonic and 





CD44high or pSTAT3high* 
(n = 29)
CD44shighpSTAT3high* 
(n = 32) P value
†
Age 0.884
    ≤ 60 (y) 8 19 19
    > 60 (y) 5 10 13
Gender 0.130
    Male 7 23 20
    Female 7 6 12
Tumor size 0.006
    ≤ 7 (cm) 11 22 13
    > 7 (cm) 3 7 19
Tumor grade <0.001
    I+II 14 23 12
    III+IV 0 6 20
T stage 0.001
    T1 11 18 8
    T2+T3 3 11 24
N stage 0.422
    N0 14 25 30
    N1+N2 0 3 2
AJCC clinical stage 0.062
    1+2 14 21 22
    3+4 0 8 10
*Low (negative to weak expression), High (moderate to strong expression); †Estimated by χ2 test.
all survival of patients 
with ccRCC (Table 6). 
However, multivariate 
analysis using Cox’s 
proportional hazards 
model determined th- 
at only tumor grade 
proved to be an inde-
pendent prognostic v- 
ariable for overall sur-




Renal cell cancer (RC- 
C) constitutes a group 
of epithelial tumors 
that are highly hetero-
geneous with respect 
to morphology and cli- 
nical behavior. We fo- 
cused on patients wi- 
th localized clear cell 
RCC (ccRCC) who un- 
derwent surgery. One 
reason is that ccRCC 
is the most prevalent 
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dedifferentiated state of neoplastic renal cells 
[18], possibly by maintaining TICs in ccRCC. 
Apart from its role as a TICs marker, CD44s 
functionally regulates TICs by activating stem 
cell genes (Nanog/Sox2/Rex1) and maintaining 
TICs features (metastasis and drug/radiation 
resistance) [8, 10]. CD44s is also required for 
the formation of EMT-associated recurrent 
breast tumors [8], and regulates the mesenchy-
mal phenotype in HCC cells [28, 29]. Our results 
here reveal a potential role of CD44s in ccRCC; 
however the detailed function of CD44s in 
ccRCC initiation and progression needs to be 
studied further. 
Our observation of a significant positive corre-
lation between CD44s and pSTAT3 overexpres-
sion in ccRCC is consistent with previous litera-
ture. Several studies demonstrated evidence 
supporting the role of CD44/STAT3 signaling in 
cancer progression. Recently, studies reported 
that CD44+ TICs had preferential activation of 
STAT3 [22, 30, 31], implying a potential role of 
pSTAT3 in maintaining CD44s+ ccRCC TICs 
which needs to be studied further. STAT3 act as 
a downstream target of CD44(s) during cancer 
cell invasion [32], chemoresistance [19, 20, 
31] and radio-resistance [10]. Additional stud-
ies have found that CD44 and STAT3 directly 
interact. For example, CD44 translocates into 
the nucleus and directly interacts with STAT3 in 
response to osteopontin [33], or CD44 inter-
acts with STAT3 in the absence of exogenous 
ligands on the membrane, functioning as a 
scaffold protein for the CD44-STAT3-JAK2 com-
plex [32]. In this paper, patients with concur-
rent CD44shigh/pSTAT3high tumor expression 
had a significant reduction in overall survival, 
although the prognostic value was not con-
firmed in the survival multivariate analysis. 
Several studies using CD44(s) monoclonal anti-
bodies have demonstrated the therapeutic 
potential of targeting CD44 by inhibiting TICs, 
such as monoclonal antibody H90 for eliminat-
ing leukaemia stem cells [34], and H4C4 for 
eliminating pancreatic cancer stem cells [10]. 
Our study here suggests that CD44s monoclo-
nal antibodies like H4C4 and pSTAT3 inhibitors 
like FLLL32 [35] may be efficacious for the 
treatment of patients diagnosed with CD44shigh/
pSTAT3high expressing ccRCC. The prognostic 
value of concurrent CD44s/pSTAT3 expression 
in ccRCC needs to be validated in a larger 
cohort of patients in the future. 
In summary, our study revealed that membrane 
CD44s and nuclear pSTAT3 were both overex-
pressed and significantly correlated in ccRCC. 
Co-expression of CD44shigh/pSTAT3high was as- 
sociated with advanced ccRCC, indicated by 
features such as, high tumor grade, large tumor 
size and advanced T stage. Taken together, our 
study indicates that the combination of CD44s 
and pSTAT3 high expression may significantly 
improve the prediction of ccRCC prognosis. 
Furthermore, the co-expression of CD44s/
pSTAT3 could be regarded as novel targets for 
therapeutic interventions in ccRCC.
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Table 6. Multivariate analysis of various prognostic markers including concurrent CD44s and pSTAT3 
high expression
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age 1.060 (1.007-1.115) 0.028* 1.050 (0.933-1.111) 0.086
Gender (female/male) 0.944 (0.327-2.723) 0.915 - -
Tumor size (> 7/≤ 7 cm) 2.129 (0.713-6.357) 0.176 - -
Tumor grade (III-IV/I-II) 3.829 (1.195-12.267) 0.024* 3.637 (1.136-11.646) 0.030*
CD44s expression (high/low) 2.673 (0.830-8.611) 0.099 - -
pSTAT3 expression (high/low)+ 31.575 (0.156-6383) 0.202 - -
CD44spSTAT3 co-expression (CD44shighpSTAT3high/CD44shigh or pSTAT3high/
CD44slowpSTAT3low)
3.113 (1.130-8.575) 0.028* 2.337 (0.849-6.434) 0.100
*HR hazard ratio, CI confidence interval.
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